Parkinson's disease (PD) is the second most important age-related neurodegenerative
disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from …

During the last decade, the serotonergic system has emerged as a key player in the
appearance of L-DOPA-induced dyskinesia in animal models of Parkinson's disease …

Background: Increased extracellular glutamate may contribute to l‐dopa induced dyskinesia,
a debilitating side effect faced by Parkinson's disease patients 5 to 10 years after l‐dopa …

Parkinson's disease (PD) is a progressive, neurodegenerative movement disorder caused
by loss of nigrostriatal dopamine (DA) neurons. DA replacement therapy using L-3, 4 …

Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the
dopaminergic system, leading to the classic motor manifestations of the disease. However …

Dopamine (DA) replacement therapy with l-3, 4-dihydroxyphenylalanine (l-DOPA) continues
to be the gold-standard treatment for Parkinson's disease (PD). Despite clear symptomatic …

Background: Levodopa-induced dyskinesia (LID) is a common motor complication of
levodopa (L-DOPA) treatment for Parkinson's disease (PD). In recent years, the role of …

Parkinson's disease is a neurodegenerative disease often characterized by motor deficits
and most commonly treated with dopamine replacement therapy. Despite its benefits …

Background: The serotonergic system is a well‐established modulator of l‐dopa‐induced
dyskinesia. To date, targeting serotonin transporters or serotonin receptor subtype 1A (5 …

Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in
the substantia nigra, the depletion of striatal dopamine and the presence of Lewy …